肿瘤防治研究2011，Vol.38Issue(3)：305-307,343,4.DOI:10.3971/j.issn.1000-8578.2011.03.017
缬沙坦和乌司他丁联合用药对肝缺血再灌注损伤的保护效应
Protective Effects of Valsartan Combined with Ulinastatin on Hepatic Ischemia-reperfusion Injury
刘义树 1黄志勇2
作者信息
- 1. 430079,武汉,湖北省肿瘤医院麻醉科
- 2. 华中科技大学附属同济医院肝脏外科中心
- 折叠
摘要
Abstract
Objective To study the protective effects of valsartan combined with/without ulinastatin on primary hepatic carcinoma with liver cirrhosis and portal hypertension in patients with hepatic ischemiareperfusion injury. Methods Thirty patients with hepatic carcinoma scheduled for hepatectomy were divided into three groups randomly: control group, ulinastatin group, valsartan and ulinastatin combined group. Ulinastatin group by 10 000 u / kg after induction of anesthesia before skin incision add 5％ glucose intravenous drip of saline 100 mi. Combined group was given valsartan orally 80 mg once daily for a week, intraoperative with ulinastatin group. Control group, 5％ glucose intravenous infusion of saline 100ml. Venous blood samples were used to measure the concentration of TXB2 and 6-keto-PGF1α, before, end and opening 60 min of the hilar blocking separately in three groups. Preoperative, postoperative 1 day, 3 days and 5 days venous blood samples for alanine aminotransferase, aspartate aminotransferase and total bilirubin measurement. Results All 30 cases had been resected successfully, three groups of patients with TXB2, 6-keto-PGF1α, alanine aminotransferase, aspartate aminotransferase and total bilirubin in plasma increased (P＜0. 05), ulinastarin group and combined group rate of increase were lower than the control group (P＜0. 05), but the protective effect of combined group and alone ulinastatin group had no significant difference (P＞0. 05). Conclusion Ulinastatin group had obvious protective effect on the patients of hilar primary hepatic carcinoma with liver cirrhosis and portal hypertension, but the effect of Ulinastatin combining with valsartan, needs to be explored further.关键词
缬沙坦/乌司他丁/缺血再灌注损伤分类
医药卫生引用本文复制引用
刘义树,黄志勇..缬沙坦和乌司他丁联合用药对肝缺血再灌注损伤的保护效应[J].肿瘤防治研究,2011,38(3):305-307,343,4.
